EcoDrugPlus

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSMZEG00005009695
Gene Symbol: LOC101486939
3 Cross references
204 Possible Orthologues:

40s Ribosomal Protein S19

Ensembl ID : ENSMZEG00005003807
Gene Symbol: LOC101467688
3 Cross references
308 Possible Orthologues:

40s Ribosomal Protein Sa

Ensembl ID : ENSMZEG00005003155
Gene Symbol: LOC101479652
4 Cross references
515 Possible Orthologues:

5'-Nucleotidase

Ensembl ID : ENSMZEG00005005679
Gene Symbol: LOC101464742
4 Cross references
180 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSMZEG00005013226
Gene Symbol: NT5E
4 Cross references
212 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSMZEG00005022234
Gene Symbol: NT5E
1 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSMZEG00005014368
Gene Symbol: HTR1AB
1 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSMZEG00005022240
Gene Symbol: HTR1B
2 Cross references
182 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSMZEG00005005700
Gene Symbol: HTR1B
1 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSMZEG00005010631
Gene Symbol: HTR1F
2 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSMZEG00005020369
Gene Symbol: HTR2A
3 Cross references
189 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSMZEG00005020424
Gene Symbol: HTR2A
1 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).